徐爱云 桂涛 黄美华 朱利 万贵平

    [摘要] 目的 探讨血清microRNAs作为生物标志物用于子宫腺肌病分子诊断的可行性。 方法 选择2015年3月～2018年3月在江苏省中西医结合医院(以下简称“我院”)经病理学确诊的子宫腺肌病患者78例作为研究组，同时收集我院健康体检中心年龄、性别与子宫腺肌病组基本匹配的78名健康体检者作为对照组。利用高通量测序技术对两组血清中的所有miRNAs进行筛选和验证。 结果 研究组血清中microRNAs的表达水平与对照组差异有统计学意义(P < 0.05)。上调的miRNA个数为316个，下调的个数为24个。进一步筛选验证后发现3个miRNA包括miR-22-3p、miR-103a-3p、miR-182-5p的AUC分别是0.900(95%CI：0.839～0.961)、0.828(95%CI：0.747～0.909)、0.844(95%CI：0.766～0.921)。结论 血清microRNAs有可能成为诊断子宫腺肌病的生物标志物。

    [关键词] 血清microRNAs；子宫腺肌病；生物标志物；分子诊断

    [中图分类号] R711.4 [文献标识码] A [文章编号] 1673-7210(2018)05(b)-0008-04

    The feasibility of serum microRNAs as biomarkers for molecular diagnosis of adenomyosis

    XU Aiyun1 GUI Tao2 HUANG Meihua2 ZHU Li2 WAN Guiping2

    1.The Third Clinical Medical College， Nanjing University of Chinese Medicine， Jiangsu Province， Nanjing 210023， China； 2.Department of Obstetrics and Gynecology， Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine， Nanjing University of Chinese Medicine， Jiangsu Province， Nanjing 210028， China

    [Abstract] Objective To explore the feasibility of using serum microRNAs as biomarkers for the molecular diagnosis of adenomyosis. Methods Seventy-eight patients with adenomyosis confirmed by the pathological diagnosis from March 2015 to March 2018 in Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine (here in after referred to as "our hospital") were selected as the study group. At the same time ......